Tempus AI, Inc. (TEM) Current Ratio: 3.13
Is Tempus AI, Inc.’s current ratio high or low?
Tempus AI, Inc.'s current ratio of 3.13 is in line with its 5-year average of 3.23, around the middle of its 5-year range (1.51–6.41).
As of Friday, June 12, 2026. 15.50% above its 12-month average of 2.71.
TEM Current Ratio Chart
TEM Average Current Ratio Chart
TEM Current vs Average Current Ratio Chart
TEM Current Ratio Metrics
CURRENT RATIO
3.13
CURRENT RATIO AVG TTM
2.71
CURRENT RATIO AVG 3Y
2.36
CURRENT RATIO AVG 5Y
3.23
CURRENT RATIO AVG 10Y
3.67
CURRENT RATIO AVG 15Y
3.67
CURRENT RATIO AVG 20Y
3.67
CURRENT VS TTM AVG
+15.50%
CURRENT VS 3Y AVG
+32.49%
CURRENT VS 5Y AVG
-3.10%
CURRENT VS 10Y AVG
-14.75%
CURRENT VS 15Y AVG
-14.75%
CURRENT VS 20Y AVG
-14.75%
TEM Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | 3.13 | 2.71 | 2.36 | 3.23 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 1.29 | 1.35 | 1.39 | 1.37 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 5.62 | 6.05 | 5.87 | 4.96 |
| Baxter International Inc. (BAX) | $10.58B | 2.31 | 1.83 | 1.71 | 1.91 |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 1.90 | 1.84 | 2.80 | 3.67 |
| Align Technology, Inc. (ALGN) | $12.64B | 1.36 | 1.29 | 1.26 | 1.29 |
| Solventum Corporation (SOLV) | $13.72B | 1.23 | 1.21 | 1.40 | 1.43 |
| Hologic, Inc. (HOLX) | $16.97B | 3.75 | 3.72 | 3.76 | 3.20 |
| 23andMe Holding Co. (ME) | $15.31M | 0.83 | 1.40 | 2.39 | 2.32 |
| Moderna, Inc. (MRNA) | $19.70B | 3.29 | 3.48 | 3.28 | 2.72 |
Liquidity Analysis
Current Ratio
3.13
Quick Ratio
3.00
Tempus AI, Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Current Ratio FAQ
- What is the current ratio for Tempus AI, Inc. (TEM)?
- The current ratio for TEM stock is 3.13.
- Is Tempus AI, Inc.'s current ratio high or low?
- Tempus AI, Inc.'s current ratio of 3.13 is in line with its 5-year average of 3.23, around the middle of its 5-year range (1.51–6.41).
- What is the TTM average current ratio for Tempus AI, Inc. (TEM)?
- The TTM average current ratio for TEM stock is 2.71.
- What is the 3Y average current ratio for Tempus AI, Inc. (TEM)?
- The 3Y average current ratio for TEM stock is 2.36.
- What is the 5Y average current ratio for Tempus AI, Inc. (TEM)?
- The 5Y average current ratio for TEM stock is 3.23.
- What is the 10Y average current ratio for Tempus AI, Inc. (TEM)?
- The 10Y average current ratio for TEM stock is 3.67.
- What is the 15Y average current ratio for Tempus AI, Inc. (TEM)?
- The 15Y average current ratio for TEM stock is 3.67.
- What is the 20Y average current ratio for Tempus AI, Inc. (TEM)?
- The 20Y average current ratio for TEM stock is 3.67.
Tempus AI, Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 3.13 |
| 2024-12-31 | 2.29 |
| 2023-12-31 | 1.51 |
| 2022-12-31 | 2.52 |
| 2021-12-31 | 3.52 |
| 2020-12-31 | 6.41 |
| 2019-12-31 | 6.32 |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky